A double-blind, randomized, placebo-controlled Phase III study to assess the efficacy of recMAGE-A3 + AS15 ASCI as adjuvant therapy in patients with MAGE-A3 positive resected stage III melanoma

Trial Profile

A double-blind, randomized, placebo-controlled Phase III study to assess the efficacy of recMAGE-A3 + AS15 ASCI as adjuvant therapy in patients with MAGE-A3 positive resected stage III melanoma

Discontinued
Phase of Trial: Phase III

Latest Information Update: 13 Jun 2018

At a glance

  • Drugs Zastumotide (Primary) ; AS15
  • Indications Malignant melanoma
  • Focus Registrational; Therapeutic Use
  • Acronyms DERMA; MAGE3-AS15-MEL-005
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 13 Jun 2018 Primary endpoint [Disease-free survival (In the gene signature-positive sub-population)] has not been met, as per the results published in the Lancet Oncology
    • 13 Jun 2018 Results evaluating efficacy published in the Lancet Oncology
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top